2025
Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms
Su D, Brown L, Bansal V, Bakkila B, Concors S, Turaga K, Gunderson C, Bergsland E, Strosberg J, Halfdanarson T, Metz D, Kunstman J, Kunz P, Gangi A. Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms. Annals Of Surgical Oncology 2025, 1-18. PMID: 40560496, DOI: 10.1245/s10434-025-17360-3.Peer-Reviewed Original ResearchPeritoneal metastasisCytoreductive surgeryConsensus guidelinesManagement of peritoneal metastasesClinical management of patientsManagement of PMManagement of patientsLevel of evidenceBackgroundNeuroendocrine neoplasmsSurgical resectionSystemic therapyNeuroendocrine neoplasmsClinical managementModified Delphi techniqueLow incidencePathway blockDisease gradeGrade 1Therapy conceptsHeterogeneous phenotypesFunctional syndromesMultidisciplinary approachRound IMetastasisNeoplasmsGestational Choriocarcinoma
Hui P. Gestational Choriocarcinoma. 2025, 117-140. DOI: 10.1007/978-3-031-83545-2_9.Peer-Reviewed Original ResearchGestational choriocarcinomaGestational trophoblastic neoplasmsDecidua of pregnancyLethal human cancersTrophoblastic neoplasmsHematogenous spreadMethotrexate chemotherapyChorionic villiPrecursor lesionsMalignant tumorsChoriocarcinomaDestructive growthSurvival rateGestationHuman cancersSarcomaTumorProliferating cellsMortality rateVillous stageChemotherapyMalignancyNeoplasmsDeciduomaPregnancyThe diversity of CD8+ T cell dysfunction in cancer and viral infection
Galluzzi L, Smith K, Liston A, Garg A. The diversity of CD8+ T cell dysfunction in cancer and viral infection. Nature Reviews Immunology 2025, 1-18. PMID: 40216888, DOI: 10.1038/s41577-025-01161-6.Peer-Reviewed Original ResearchChronic viral infectionsCD8+ T cellsViral infectionT cellsCD8+ T cell dysfunctionT cell dysfunctionClinical management of cancerChronically infected cellsManagement of cancerAntigenic stimulationClinical managementHypofunctional stateTherapeutic strategiesInfectionCancerInfected cellsCell deathPathological scenariosPrevent exhaustionCD8AnergyCellsNeoplasmsHypofunctionDysfunctionTumors of the sellar region
Baehring J, Shih H, Chen Z, Santagata S. Tumors of the sellar region. 2025, 245-263. DOI: 10.1093/med/9780198869702.003.0023.Peer-Reviewed Original ResearchSellar regionPrognosis of craniopharyngiomasSpindle cell oncocytomaGranular cell tumorNeuroendocrine tumorsPituitary blastomaClinical presentationCell tumorsPediatric neoplasmsMolecular pathogenesisTumorMolecular featuresAbstract TumorsDiagnosisBlastomaPituicytomaCraniopharyngiomaOncocytomaNeoplasmsPrognosisHybrid granular cell tumor/perineurioma: a report of two rare cases with PIK3CA mutations
Toklu A, Panse G, Jour G, Linos K, Cloutier J, Dehner C. Hybrid granular cell tumor/perineurioma: a report of two rare cases with PIK3CA mutations. Virchows Archiv 2025, 1-8. PMID: 40159563, DOI: 10.1007/s00428-025-04089-3.Peer-Reviewed Original ResearchPeripheral nerve sheath tumorsHybrid peripheral nerve sheath tumorsRare mesenchymal neoplasmNerve sheath tumorsWell-circumscribed lesionGLUT1 stainingPIK3CA mutationsUnusual neoplasmsSheath tumorsMesenchymal neoplasmsRare caseDual differentiationDifferential diagnosisPathological spectrumMolecular testingGranular cell componentPathogenic mutationsTumorPerineurial cellsPIK3CANeoplasmsPerineuriomaMolecular featuresGranular cellsMolecular analysis
2024
Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms
Hong Y, Pasca S, Shi W, Puiu D, Lake N, Lek M, Ru M, Grove M, Prizment A, Joshu C, Platz E, Guallar E, Arking D, Gondek L. Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms. Nature Communications 2024, 15: 10133. PMID: 39578475, PMCID: PMC11584845, DOI: 10.1038/s41467-024-54443-3.Peer-Reviewed Original ResearchConceptsClonal hematopoiesis of indeterminate potentialClonal hematopoiesisVariant allele fractionHeteroplasmic variantsIndeterminate potentialMyeloid neoplasmsHeteroplasmyMultiple mutationsAllele fractionMutationsHigh-risk groupPathogenic risk factorsMarkersRisk score modelDeleteriousnessSpliceosomeHematologic malignanciesRisk stratificationNeoplasm developmentNeoplasmsNeoplasm incidenceRisk factorsVariantsTERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up
Abi-Raad R, Shi Q, Chen F, Antony V, Hsiao W, Simsir A, Liu X, Brandler T, Cai G. TERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up. American Journal Of Clinical Pathology 2024, 163: 251-257. PMID: 39250709, DOI: 10.1093/ajcp/aqae117.Peer-Reviewed Original ResearchTERT promoter mutationsHistopathologic follow-upFine-needle aspirationTERT mutationsMolecular alterationsFollow-upPromoter mutationsThyroid carcinomaFine-needle aspiration diagnosisFine-needle aspiration specimensThyroid fine-needle aspiration specimensBenign thyroid neoplasmsSurgical Follow-UpAssociated with malignancyMulti-institutional studyThyroSeq v3Thyroid neoplasmsAspiration specimensTumor behaviorMalignant neoplasmsCarcinomaMalignancyNeoplasmsThyroidMutationsMixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation
Yurtsever N, Lee E, Pinatti L, Shah B, Tormey C, Siddon A. Mixed-field ABO front typing as an early sign of disease recurrence in ABO-matched stem cell transplantation. Immunohematology 2024, 40: 89-92. PMID: 39373301, PMCID: PMC11700658, DOI: 10.2478/immunohematology-2024-013.Peer-Reviewed Original ResearchConceptsStem cell transplantationCell transplantationDisease recurrenceMyeloid neoplasmsChimerism testingAllogeneic stem cell transplantationSigns of disease recurrenceIndicator of disease recurrenceDonor-recipient pairsABO antigen expressionGraft statusAntigen expressionFemale patientsPost-transplantationAllograft statusTransplantationABO typeRecurrenceClinical settingEarly signsNeoplasmsChimerismEarly indicatorABOEngraftmentTaste dysfunction after endoscopic endonasal resection of olfactory groove meningioma: Case series and review of the literature
Fecker A, Studer M, Manes R, Omay S, Detwiller K, Smith T, Andersen P, Sanusi O, Collins K, Geltzeiler M, Rimmer R. Taste dysfunction after endoscopic endonasal resection of olfactory groove meningioma: Case series and review of the literature. American Journal Of Otolaryngology 2024, 45: 104302. PMID: 38678798, DOI: 10.1016/j.amjoto.2024.104302.Peer-Reviewed Original ResearchResection of olfactory groove meningiomasOlfactory groove meningiomasEndoscopic endonasal resectionMinority of patientsSense of tasteTaste changesSeverity of symptomsOlfactory dysfunctionTaste dysfunctionMedian timeCase seriesClinical characteristicsOlfactory functionPatient counselingPatientsSense of smellAssociated with lateralizationResectionMeningiomasSurgeryDysfunctionRated severityNeoplasmsSurvey responsesAgeusiaThe Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms
Chen A, Sharma N, Patel P, Olivares S, Bahrami A, Barnhill R, Blokx W, Bosenberg M, Busam K, de La Fouchardière A, Duncan L, Elder D, Ko J, Landman G, Lazar A, Lezcano C, Lowe L, Maher N, Massi D, Messina J, Mihic-Probst D, Parker D, Redpath M, Scolyer R, Shea C, Spatz A, Tron V, Xu X, Yeh I, Yun S, Zembowicz A, Gerami P. The Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms. The American Journal Of Surgical Pathology 2024, 48: 708-718. PMID: 38590014, DOI: 10.1097/pas.0000000000002226.Peer-Reviewed Original ResearchConceptsDesmoplastic melanomaMelanocytic neoplasmsNext-generation sequencingInterobserver agreementDiagnostic accuracyHematoxylin and eosin sectionsImpact of next-generation sequencingDiagnostic scenariosMetastatic diseaseDesmoplastic tumorsMelanocytic tumorsMelanoma casesMelanoma geneticsFleiss' multirater kappaAccurate diagnosisNeoplasmsMelanomaAncillary toolDegree of improvementMultirater kappaDiagnosisGenomic findingsTumorGenome sequencing resultsPathologistsBRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms
Gerami P, Chen A, Sharma N, Patel P, Hagstrom M, Kancherla P, Geraminejad T, Olivares S, Biswas A, Bosenberg M, Busam K, de La Fouchardière A, Duncan L, Elder D, Ko J, Landman G, Lazar A, Lowe L, Massi D, Mihic-Probst D, Parker D, Scolyer R, Shea C, Zembowicz A, Yun S, Blokx W, Barnhill R. BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms. The American Journal Of Surgical Pathology 2024, 48: 538-545. PMID: 38525831, DOI: 10.1097/pas.0000000000002194.Peer-Reviewed Original ResearchDNA Methylation Profiling Enables Accurate Classification of Nonductal Primary Pancreatic Neoplasms
Verschuur A, Hackeng W, Westerbeke F, Benhamida J, Basturk O, Selenica P, Raicu G, Molenaar I, van Santvoort H, Daamen L, Klimstra D, Yachida S, Luchini C, Singhi A, Geisenberger C, Brosens L. DNA Methylation Profiling Enables Accurate Classification of Nonductal Primary Pancreatic Neoplasms. Clinical Gastroenterology And Hepatology 2024, 22: 1245-1254.e10. PMID: 38382726, DOI: 10.1016/j.cgh.2024.02.007.Peer-Reviewed Original ResearchConceptsPancreatic neoplasmsMachine learning modelsAnalysis of biopsy specimensNonpancreatic neoplasmsNon-pancreatic originDiagnosis of pancreatic neoplasmsPrimary pancreatic neoplasmDiagnostic work-upArea under the curvePre-operative settingLearning modelsMethylation profilesPrimary tumorBiopsy specimensHistopathological diagnosisResected samplesDetecting neoplasmsDNA methylation signaturesTumor typesCancer entitiesLogistic regression modelsNeoplasmsClassifier performanceNeural networkConcordant classification
2023
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, Medeiros L, Wang M, Cohen J, Churnetski M, Hill B, Sawalha Y, Hernandez-Ilizaliturri F, Kothari S, Vose J, Bast M, Fenske T, Gari S, Maddocks K, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan A, Wagner-Johnston N, Messmer M, Mehta A, Anderson J, Reddy N, Kovach A, Landsburg D, Glenn M, Inwards D, Ristow K, Karmali R, Kaplan J, Caimi P, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual J, Lue J, Diefenbach C, Fisher R, Barta S. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Advances 2023, 7: 7393-7401. PMID: 37874912, PMCID: PMC10758713, DOI: 10.1182/bloodadvances.2023010757.Peer-Reviewed Original ResearchConceptsProgression-free survivalMantle cell lymphomaOverall survivalPleomorphic variantMedian progression-free survivalB-cell non-Hodgkin lymphomaOutcomes of patientsAutologous hematopoietic transplantationNon-Hodgkin lymphomaComplete responsePatient characteristicsPoor prognosisHematopoietic transplantationCell lymphomaSecondary objectiveMonthsPatientsLymphomaSurvivalHigher scoresPrimary objectivePrognosisTransplantationNeoplasmsAre We Ready For “Triplet” Therapy in Higher-Risk MDS?
Brunner A, Platzbecker U, DeZern A, Zeidan A. Are We Ready For “Triplet” Therapy in Higher-Risk MDS? Clinical Hematology International 2023, 5: 23-32. PMID: 37933301, PMCID: PMC10625655, DOI: 10.46989/001c.88301.Peer-Reviewed Original ResearchAcute myeloid leukemiaCombination chemotherapyPatient populationOnly disease-modifying therapyNovel combination chemotherapyOngoing therapeutic challengeOlder patient populationUnique patient populationDisease-modifying therapiesCurrent treatment paradigmsTherapeutic challengeTreatment paradigmEffective therapyMyeloid leukemiaNew therapiesAppropriate endpointsTherapyChemotherapyComorbiditiesPatientsTransplantNeoplasmsLeukemiaPopulationDecitabineHistology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study
Hou T, Yang Z, Zhang Q, Zhang X, Liao X, Lin J. Histology Shift in Esophageal Cancer Between Biopsies and Resections After Neoadjuvant Therapy: A Pilot Study. International Journal Of Surgical Pathology 2023, 32: 920-925. PMID: 37899731, DOI: 10.1177/10668969231208029.Peer-Reviewed Original ResearchNeoadjuvant therapyEsophageal adenocarcinomaNeuroendocrine neoplasmsNeuroendocrine carcinomaSurvival rateOverall median survival timeEsophageal neuroendocrine carcinomaPreoperative neoadjuvant therapyAdvanced esophageal adenocarcinomaMedian survival timeObserved survival ratesMainstay treatmentResidual adenocarcinomaConventional adenocarcinomaEsophageal cancerNeuroendocrine morphologyFocal positivitySurvival timeNeuroendocrine componentAdenocarcinomaBiopsyResectionSmall seriesPatientsNeoplasmsUpdates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms
Badar T, Madanat Y, Zeidan A. Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms. Future Oncology 2023, 19: 1877-1889. PMID: 37750305, DOI: 10.2217/fon-2023-0454.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsErythropoiesis-stimulating agentsTreatment-naive patientsHigh-risk patientsMeaningful efficacyIndolent courseDismal prognosisRandomized trialsRisk stratificationNeoplasm patientsSerial monitoringClinical trialsNovel therapiesPatientsAppropriate managementModest responseGood responseNeoplasmsTrialsNovel compoundsLuspaterceptLenalidomidePrognosisAnemiaTherapyMore needsRacial Disparities in Surgical Versus Nonsurgical Management of Distal Radius Fractures in a Medicare Population
Joo P, Halperin S, Dhodapkar M, Adeclat G, Elaydi A, Wilhelm C, Grauer J. Racial Disparities in Surgical Versus Nonsurgical Management of Distal Radius Fractures in a Medicare Population. Hand 2023, 20: 258-262. PMID: 37737570, PMCID: PMC11833841, DOI: 10.1177/15589447231198267.Peer-Reviewed Original ResearchDistal radius fracturesRace/ethnicityNonsurgical managementMultivariable analysisRadius fracturesMedicare populationIsolated distal radius fractureSurgical Versus Nonsurgical ManagementIndependent predictorsSurgical managementEquitable carePatientsFracture typeEthnic disparitiesSurgeryNational databaseRacial disparitiesComorbiditiesEthnicityFracturesDisparitiesManagementPolytraumaNeoplasmsPopulationClassification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
Stahl M, Bewersdorf J, Xie Z, Porta M, Komrokji R, Xu M, Abdel-Wahab O, Taylor J, Steensma D, Starczynowski D, Sekeres M, Sanz G, Sallman D, Roboz G, Platzbecker U, Patnaik M, Padron E, Odenike O, Nimer S, Nazha A, Majeti R, Loghavi S, Little R, List A, Kim T, Hourigan C, Hasserjian R, Halene S, Griffiths E, Gore S, Greenberg P, Figueroa M, Fenaux P, Efficace F, DeZern A, Daver N, Churpek J, Carraway H, Buckstein R, Brunner A, Boultwood J, Borate U, Bejar R, Bennett J, Wei A, Santini V, Savona M, Zeidan A. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews 2023, 62: 101128. PMID: 37704469, DOI: 10.1016/j.blre.2023.101128.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInternational consensus classificationResponse assessmentWorld Health Organization classificationPatient-centered careRisk assessment toolClinical outcomesRisk stratificationOrganization classificationCentered careTherapeutic benefitTherapeutic outcomesConsensus classificationResponse criteriaInternational ConsortiumNeoplasmsLife assessmentAssessment toolOutcomesReportAssessmentPrognosticationCareTreatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists
Madanat Y, Zeidan A. Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists. Clinics In Laboratory Medicine 2023, 43: 685-698. PMID: 37865511, DOI: 10.1016/j.cll.2023.07.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBone marrow biopsy reportsAvailable treatment optionsBest therapeutic approachClinical presentationPathologic findingsRisk stratificationTherapeutic optionsTreatment optionsBiopsy reportsDisease entityTherapeutic approachesTreatment considerationsAccurate diagnosisGenetic abnormalitiesDiagnosisDisease subclassificationPatientsNeoplasmsHematopathologistsOptionsPrognosticationAbnormalitiesCliniciansSubclassificationMolecular findings in myeloid neoplasms
Tran T, Siddon A. Molecular findings in myeloid neoplasms. International Journal Of Laboratory Hematology 2023, 45: 442-448. PMID: 37345257, DOI: 10.1111/ijlh.14118.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid neoplasmsNext-generation sequencingMyeloproliferative neoplasmsInternational diagnostic guidelinesSomatic gene mutationsHematologic cancersMyeloid leukemiaDiagnostic guidelinesClinical relevanceMyeloid disordersPatient careNeoplasmsCytogenetic findingsMolecular findingsGene mutationsNew molecular technologiesMolecular technologiesMutationsLeukemiaCancerPrognosticationCliniciansFindingsModifier mutations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply